' 
SCIENTIFIC SCORE
Moderately Effective
Based on 16 Researches
8.7
USERS' SCORE
Good
Based on 1 Review
8.5
Supplement Facts
Serving Size: About 1/4 cup (31 g)
Amount Per Serving
%DV
Calories
180
Total Fat
13 g
17%
Saturated Fat
3 g
15%
Trans Fat
0 g
Cholesterol
0 mg
0%
Sodium
0 mg
0%
Total Carbohydrate
4 g
1%
Dietary Fiber
2 g
7%
Total Sugars
0 g
Includes 0g Added Sugars
0%
Protein
11g
Vit. D
0 mcg
0%
Calcium
8 mg
0%
Iron
4 mg
20%
Potassium
243 mg
6%
Top Medical Research Studies
9
Kaiso inhibitors show lung cancer promise
Design, synthesis and evaluation of diphenyl ether-based kaiso inhibitors with enhanced potency.
Focused treatment for lung cancer
We focused on Kaiso, a protein that could be key in treating lung cancer, and sought to understand how inhibitors of this protein might work. Our approach involved virtual screening and molecular dynamic simulations. Through this, we identified compound 5 (ZINC20577650) as a potential Kaiso inhibitor.
By tweaking the structure of compound 5, we created a new group of inhibitors, all featuring a diphenyl ether ring. Among these, compound 20 emerged as the standout, showing strong inhibitory activity against lung cancer cells known as A549, with an impressive IC value of 0.34 μM. This performance was notably better than the current positive control, MIRA-1.
We delved deeper into the mechanisms behind this effectiveness. Our molecular docking and dynamics studies revealed how certain parts of compound 20 engage with the Kaiso protein's active site. The interaction between the compound's amino and ester components with the protein, along with the extension of a benzene ring, plays a crucial role in boosting its potency. These discoveries offer promising new directions for Kaiso inhibitor development.
By tweaking the structure of compound 5, we created a new group of inhibitors, all featuring a diphenyl ether ring. Among these, compound 20 emerged as the standout, showing strong inhibitory activity against lung cancer cells known as A549, with an impressive IC value of 0.34 μM. This performance was notably better than the current positive control, MIRA-1.
We delved deeper into the mechanisms behind this effectiveness. Our molecular docking and dynamics studies revealed how certain parts of compound 20 engage with the Kaiso protein's active site. The interaction between the compound's amino and ester components with the protein, along with the extension of a benzene ring, plays a crucial role in boosting its potency. These discoveries offer promising new directions for Kaiso inhibitor development.
Read More
9
Ivonescimab shows improved PFS
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.
Focus on PD-L1 lung cancer
We investigated the effectiveness of ivonescimab, a bispecific antibody targeting both programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), against pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC) expressing PD-L1. Conducted as a randomised, double-blind, phase 3 trial in China, the study involved 398 patients.
Participants were assigned to receive either ivonescimab or pembrolizumab and were closely monitored for their progression-free survival (PFS). The results showed that ivonescimab offered a significantly longer median PFS of 11.1 months compared to 5.8 months for pembrolizumab, showcasing its potential as a new treatment option.
Additionally, while some patients experienced grade 3 or higher treatment-related side effects, ivonescimab exhibited a manageable safety profile. Importantly, this study highlights ivonescimab's promising role in the first-line treatment of PD-L1-positive advanced NSCLC patients, providing a hopeful avenue for those affected by this disease.
Participants were assigned to receive either ivonescimab or pembrolizumab and were closely monitored for their progression-free survival (PFS). The results showed that ivonescimab offered a significantly longer median PFS of 11.1 months compared to 5.8 months for pembrolizumab, showcasing its potential as a new treatment option.
Additionally, while some patients experienced grade 3 or higher treatment-related side effects, ivonescimab exhibited a manageable safety profile. Importantly, this study highlights ivonescimab's promising role in the first-line treatment of PD-L1-positive advanced NSCLC patients, providing a hopeful avenue for those affected by this disease.
Read More
8
GCA induces pyroptosis in lung CSCs
Golgicide A induces pyroptosis of lung cancer stem cells by regulating dTGN formation via GOLPH3/MYO18A complex.
Study directly explores protein treatment
We examined the impact of a protein treatment known as golgicide A (GCA) on lung cancer stem cells (CSCs), which are notorious for fueling tumor growth and making treatment more difficult. By using a specific culture method to create these stem cells, we assessed how GCA affects their viability and overall health.
Our tests showed that GCA effectively induced a form of cell death known as pyroptosis in both H1650 and A549-derived CSCs. This dramatic effect appears to stem from GCA enhancing the interaction between two proteins, GOLPH3 and MYO18A. This interaction leads to changes in the structure of the cells' trans-Golgi network, which in turn recruits another protein involved in the pyroptosis process.
We also conducted an animal study that confirmed GCA's potential to inhibit tumor growth in a living organism. These findings provide encouraging insight into how GCA targets cancer stem cells, presenting a promising avenue for future treatments against lung cancer.
Our tests showed that GCA effectively induced a form of cell death known as pyroptosis in both H1650 and A549-derived CSCs. This dramatic effect appears to stem from GCA enhancing the interaction between two proteins, GOLPH3 and MYO18A. This interaction leads to changes in the structure of the cells' trans-Golgi network, which in turn recruits another protein involved in the pyroptosis process.
We also conducted an animal study that confirmed GCA's potential to inhibit tumor growth in a living organism. These findings provide encouraging insight into how GCA targets cancer stem cells, presenting a promising avenue for future treatments against lung cancer.
Read More
Most Useful Reviews
9
High protein benefit
This has proven useful for cancer patients, particularly due to its high protein content.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 16 Researches
8.7
9.5
Novel ALK fusion therapy discovery
TTC7A-ALK, a novel ALK fusion variant identified in a patient with metastatic lung adenocarcinoma, exhibits excellent response to crizotinib.
Study highlights sequential treatment effectiveness
Our investigation focused on a novel fusion variant, TTC7A-ALK, found in a patient with advanced lung adenocarcinoma. The patient, diagnosed through targeted next-generation sequencing, received crizotinib treatment after the discovery of this fusion. Remarkably, this treatment led to a progression-free survival of 29 months.
We further explored how this fusion protein behaves, comparing it to the well-known EML4-ALK. We observed that TTC7A-ALK not only promotes cell growth in vitro but also increases tumor formation in animal models, and this effect is suppressed by crizotinib. On a cellular level, introducing the TTC7A-ALK fusion into certain cells resulted in heightened activity in crucial signaling pathways, which crizotinib was able to inhibit.
As the patient's cancer progressed, transitioning to alectinib brought rapid symptom relief and controlled most of the affected areas. Overall, this study highlights the potential of TTC7A-ALK as a promising therapeutic target for ALK inhibitors. It emphasizes the importance of identifying rare fusions in lung cancer, paving the way for more personalized treatment strategies.
We further explored how this fusion protein behaves, comparing it to the well-known EML4-ALK. We observed that TTC7A-ALK not only promotes cell growth in vitro but also increases tumor formation in animal models, and this effect is suppressed by crizotinib. On a cellular level, introducing the TTC7A-ALK fusion into certain cells resulted in heightened activity in crucial signaling pathways, which crizotinib was able to inhibit.
As the patient's cancer progressed, transitioning to alectinib brought rapid symptom relief and controlled most of the affected areas. Overall, this study highlights the potential of TTC7A-ALK as a promising therapeutic target for ALK inhibitors. It emphasizes the importance of identifying rare fusions in lung cancer, paving the way for more personalized treatment strategies.
Read More
9
IAP inhibition enhances tumor immunity
Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer.
Focus on immune response in cancer
We explored the role of a protein complex involving Liver Kinase B1 (LKB1), Inhibitor of Apoptosis Protein (IAP), and Janus Kinase 1 (JAK1) in the context of lung cancer with specific LKB1 mutations. This study was particularly focused on how these proteins can create resistance to immune responses, which is a significant hurdle in effectively treating this type of cancer.
By inhibiting IAP, we observed that the immune response became markedly more robust. The treatment led to noticeable increases in a crucial immune pathway related to the Stimulator of Interferon Genes (STING) and improved the ability of immune cells to infiltrate the tumors. Importantly, these effects were tested in a model that reflected LKB1-mutant lung cancer in immune-competent mice.
Our findings suggest that strategies targeting the IAP-JAK1 pathway with specific inhibitors may be a promising avenue for restoring the effectiveness of existing therapies, such as immune checkpoint inhibitors. This approach could potentially turn unresponsive, cold tumors into ones that are open to immune attack.
By inhibiting IAP, we observed that the immune response became markedly more robust. The treatment led to noticeable increases in a crucial immune pathway related to the Stimulator of Interferon Genes (STING) and improved the ability of immune cells to infiltrate the tumors. Importantly, these effects were tested in a model that reflected LKB1-mutant lung cancer in immune-competent mice.
Our findings suggest that strategies targeting the IAP-JAK1 pathway with specific inhibitors may be a promising avenue for restoring the effectiveness of existing therapies, such as immune checkpoint inhibitors. This approach could potentially turn unresponsive, cold tumors into ones that are open to immune attack.
Read More
9
Ivonescimab shows improved PFS
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.
Focus on PD-L1 lung cancer
We investigated the effectiveness of ivonescimab, a bispecific antibody targeting both programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), against pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC) expressing PD-L1. Conducted as a randomised, double-blind, phase 3 trial in China, the study involved 398 patients.
Participants were assigned to receive either ivonescimab or pembrolizumab and were closely monitored for their progression-free survival (PFS). The results showed that ivonescimab offered a significantly longer median PFS of 11.1 months compared to 5.8 months for pembrolizumab, showcasing its potential as a new treatment option.
Additionally, while some patients experienced grade 3 or higher treatment-related side effects, ivonescimab exhibited a manageable safety profile. Importantly, this study highlights ivonescimab's promising role in the first-line treatment of PD-L1-positive advanced NSCLC patients, providing a hopeful avenue for those affected by this disease.
Participants were assigned to receive either ivonescimab or pembrolizumab and were closely monitored for their progression-free survival (PFS). The results showed that ivonescimab offered a significantly longer median PFS of 11.1 months compared to 5.8 months for pembrolizumab, showcasing its potential as a new treatment option.
Additionally, while some patients experienced grade 3 or higher treatment-related side effects, ivonescimab exhibited a manageable safety profile. Importantly, this study highlights ivonescimab's promising role in the first-line treatment of PD-L1-positive advanced NSCLC patients, providing a hopeful avenue for those affected by this disease.
Read More
9
Effective targeting of lung cancer
Selective depletion of CCR8+Treg cells enhances anti-tumor immunity of cytotoxic T cells in lung cancer via dendritic cells.
Protein treatment strategy evaluated
We explored how targeting C-C Motif Chemokine Receptor 8 (CCR8), which is found on immune-suppressing regulatory T (Treg) cells in tumors, could improve immune responses against non-small cell lung cancer (NSCLC). In our study, we utilized several mouse models of NSCLC to evaluate the effectiveness of combining an anti-CCR8 antibody with a PD1 inhibitor, a well-known immunotherapy drug.
Our results showed a promising reduction in tumor growth when this combination was used, without causing major side effects like drastic weight loss or severe inflammation. We also performed advanced tests, including single-cell RNA and T-cell receptor sequencing, which allowed us to observe that this combined treatment reshaped the tumor environment. It effectively disrupted the interaction between CCR8+ Treg cells and CCL5+ dendritic cells, which are crucial for activating the immune system.
By eliminating CCR8+ Treg cells along with the PD1 inhibitor, we found a significant increase in interleukin-12 production, which enhanced the immune activity of CD8+ T cells. This treatment approach was also noted to have potential benefits in clinical patients with advanced NSCLC receiving the CCR8 antibody LM-108 alongside existing therapies. Overall, we believe that targeting CCR8 on Treg cells is a promising strategy for overcoming the immune suppression seen in lung cancer.
Our results showed a promising reduction in tumor growth when this combination was used, without causing major side effects like drastic weight loss or severe inflammation. We also performed advanced tests, including single-cell RNA and T-cell receptor sequencing, which allowed us to observe that this combined treatment reshaped the tumor environment. It effectively disrupted the interaction between CCR8+ Treg cells and CCL5+ dendritic cells, which are crucial for activating the immune system.
By eliminating CCR8+ Treg cells along with the PD1 inhibitor, we found a significant increase in interleukin-12 production, which enhanced the immune activity of CD8+ T cells. This treatment approach was also noted to have potential benefits in clinical patients with advanced NSCLC receiving the CCR8 antibody LM-108 alongside existing therapies. Overall, we believe that targeting CCR8 on Treg cells is a promising strategy for overcoming the immune suppression seen in lung cancer.
Read More
9
NK cells plus atezolizumab boost immunity
Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer.
Combination therapy relevance noted
We explored how the combination of natural killer (NK) cells and the protein atezolizumab can improve treatment outcomes for small cell lung cancer (SCLC), a particularly aggressive form of this disease. By expanding and activating NK cells, we aimed to see if pairing them with atezolizumab—an immune checkpoint inhibitor that targets the PD-L1 protein—could enhance anti-cancer effects.
During our research, we observed that introducing expanded NK cells alongside atezolizumab significantly increased their potency against SCLC cells. We noted a rise in cytotoxic activity, marked by greater production of key immune molecules, leading to a more effective attack on tumor growth. Remarkably, this combination not only inhibited tumor development but also extended the survival of mice in our studies.
Our findings suggest that this innovative approach could pave the way for more advanced immunotherapies that may eventually benefit patients with SCLC. These results hold promise as they improve our understanding of how a strategic combination of proteins and immune cells can make a difference in cancer treatment.
During our research, we observed that introducing expanded NK cells alongside atezolizumab significantly increased their potency against SCLC cells. We noted a rise in cytotoxic activity, marked by greater production of key immune molecules, leading to a more effective attack on tumor growth. Remarkably, this combination not only inhibited tumor development but also extended the survival of mice in our studies.
Our findings suggest that this innovative approach could pave the way for more advanced immunotherapies that may eventually benefit patients with SCLC. These results hold promise as they improve our understanding of how a strategic combination of proteins and immune cells can make a difference in cancer treatment.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.5
9
High protein benefit
This has proven useful for cancer patients, particularly due to its high protein content.
